[Courtesy of SK bioscience]
An updated non-mRNA Covid-19 vaccine developed by U.S. biotechnology firm Novavax Inc. will be made available in South Korea starting from December 18, 2023.
Korea’s SK bioscience Co. announced on Tuesday that it will supply the synthetic antigen-based Covid-19 vaccine developed by the U.S. biotechnology firm and specifically targeting the Omicron subvariant XBB.1.5, to medical institutions and public health centers nationwide.
SK Bioscience has secured a license to import the Novavax vaccine, which was approved for emergency use for individuals aged 12 and above from the Ministry of Food and Drug Safety on November 29, 2023.
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) also approved the vaccine for emergency use the month before.
By Kim Jee-hee and Yoon Yeon-hae
[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]